Systematic review reveals benefits of combining PD-1/PD-L1 inhibitors with chemotherapy in locally advanced gastric cancer, suggesting potential for improved outcomes.
Key Points
Combination therapy shows increased effectiveness in improving response rates in gastric cancer patients.
Key metrics indicate a significant response rate improvement of about 30% in neoadjuvant settings.
Systematic review and meta-analysis evaluated multiple clinical trials assessing the efficacy of this combined approach.
Further validation needed across diverse patient demographics to strengthen these findings.